BIT 10.3% 6.1¢ biotron limited

Merck did a Joint Venture with Ridgeback Biotherapeutics to...

  1. 499 Posts.
    lightbulb Created with Sketch. 273


    Merck did a Joint Venture with Ridgeback Biotherapeutics to release the Covid-19 treatment molnupiravir.

    Yes, they have beaten BIT to the punch so far.
    As far as I know, it is also a small molecule drug.

    There can be little excuses from MM on the commercial aspects of the business such as dealmaking .


    But the fight is far from over with covid19.
    Covid19 is going to be around for a while.
    The opportunity is still present.

    MM would do well to analyse what Ridgeback Biotherapeutics did right to secure a deal with Big Pharma!!!
    I note...
    molnupiravir is not 100% effective...and it doesn't have to be!!!

    ie.
    Did you know they tested their candidate against covid19 using ferrets?
    There was a reason for that also.
    Some of the testing was sponsored by the US government also for this drug!

    BIT need to do a JV deal with the remaining Big Pharma with their best covid19 candidates or a deal with the governments.

    They need to partner with Big Pharma or Government to take advantage of the fastracking.
    There is a huge unmet need still.

    Fortunately for BIT, there is the covid19 candidates and the BIT225 for HIV!
    With the appropriate deal, BIT would easily become a multibagger.

    The focus needs to be solely on the dealmaking with Big Pharma.

    GLA BIT holders






 
watchlist Created with Sketch. Add BIT (ASX) to my watchlist
(20min delay)
Last
6.1¢
Change
-0.007(10.3%)
Mkt cap ! $55.03M
Open High Low Value Volume
7.0¢ 7.2¢ 5.5¢ $418.3K 6.837M

Buyers (Bids)

No. Vol. Price($)
1 85063 6.1¢
 

Sellers (Offers)

Price($) Vol. No.
6.3¢ 14900 2
View Market Depth
Last trade - 16.10pm 26/04/2024 (20 minute delay) ?
Last
6.1¢
  Change
-0.007 ( 10.3 %)
Open High Low Volume
7.0¢ 7.0¢ 5.6¢ 1208244
Last updated 15.44pm 26/04/2024 ?
BIT (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.